10 completed, 1 terminated. 7 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 1 | Terminated 1 |
Follow Stage IV Uterine Sarcoma: new trials by email Literature Review of Stage IV Uterine Sarcoma trials Research Report on Stage IV Uterine Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer Medical Chart Review, Questionnaire Administration - Recurrent Cervical Carcinoma, Recurrent Uterine Corpus Carcinoma | Completed | Gynecologic Oncology Group | 778 | 2010-07-01 | 2018-04-12 | |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery therapeutic angiotensin-(1-7), laboratory biomarker analysis - Bone Cancer, Chondrosarcoma | Phase 2 | Completed | Wake Forest University Health Sciences | 20 | 2009-10-01 | 2018-07-05 |
| Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies stereotactic radiosurgery, quality-of-life assessment - Fallopian Tube Cancer, Ovarian Sarcoma | Phase 2 | Completed | Case Comprehensive Cancer Center | 50 | 2009-05-01 | 2013-11-28 |
| AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-02-01 | 2018-06-29 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 63 | 2006-09-01 | 2015-12-07 |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma sorafenib tosylate - Adult Angiosarcoma, Adult Epithelioid Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 147 | 2005-09-01 | 2014-05-23 |
| Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer sorafenib tosylate - Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 56 | 2005-02-01 | 2015-11-20 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer EF5, motexafin lutetium, pharmacological study - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Not applicable | Terminated | National Cancer Institute (NCI) | 30 | 2004-05-01 | 2013-01-16 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma tanespimycin, pharmacological study - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 1999-10-01 | 2013-02-07 |
Sarcoma (6) · Carcinoma, Ovarian Epithelial (4) · Chondrosarcoma (3) · Fallopian Tube Neoplasms (3) · Histiocytoma, Malignant Fibrous (3) · Leiomyosarcoma (3) · Osteosarcoma (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Dermatofibrosarcoma (2) · Endometrial Neoplasms (2) · Fibrosarcoma (2) · Gastrointestinal Stromal Tumors (2) · Hemangiosarcoma (2) · Liposarcoma (2)
Neoplasms (10) · Neoplasms by Histologic Type (9) · Neoplasms by Site (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Neoplasms, Connective Tissue (6) · Neoplasms, Connective and Soft Tissue (6) · Neoplasms, Glandular and Epithelial (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Adnexal Diseases (4) · Carcinoma (4)
Sorafenib (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · HhAntag691 (1) · Radiosurgery (1) · Sirolimus (1) · Vinorelbine (1) · aflibercept (1) · angiotensin I (1-7) (1) · motexafin lutetium (1) · saracatinib (1) · tanespimycin (1) · temsirolimus (1)
National Cancer Institute (NCI) (7) · Case Comprehensive Cancer Center (1) · Gynecologic Oncology Group (1) · University of Southern California (1) · Wake Forest University Health Sciences (1)
United States (11) · Canada (3)
Agustin Garcia (1) · Amit Oza (1) · Gini Fleming (1) · Margaret von Mehren (1) · Mrinal Gounder (1) · Ramesh Ramanathan (1) · Robert DeBernardo, MD (1) · Robert Maki (1) · Sandra Brooks (1) · Stephen Michael Hahn (1) · William Petty (1)
N01CM62203 (3), N01CM62201 (2), N01CM62206 (2), P30CA008748 (2), N01CM62209 (1), P01CA087971 (1), U01CA069856 (1), U01CA099168 (1), U10CA101165 (1)